Jonsson-Schmunk Kristina, Croyle Maria A
Division of Pharmaceutics, University of Texas at Austin, College of Pharmacy, 2409 W University Ave, Austin, TX 78712, USA.
Expert Rev Anti Infect Ther. 2015 May;13(5):527-30. doi: 10.1586/14787210.2015.1028368. Epub 2015 Mar 23.
In response to the severity and scale of the 2014 Ebola outbreak, several experimental vaccines were granted fast-track status for clinical testing. Although they may provide long-lasting protection from Ebola, they are, in their current states, far from optimal for populations that need them the most. In this context, nasal immunization addresses the: immune response required at the mucosa where Ebola initiates infection; needs of a population in terms of cost and compliance; and potency of each platform as they contain viruses that naturally infect the respiratory tract. Understanding the attributes of nasal immunization and its application will lead to potent vaccines that can effectively end Ebola and other emerging infectious diseases in developing and industrialized countries.
针对2014年埃博拉疫情的严重程度和规模，几种实验性疫苗被授予临床试验的快速通道地位。尽管它们可能提供对埃博拉的长期保护，但就目前的状态而言，对于最需要它们的人群来说远非最佳选择。在这种背景下，鼻内免疫解决了以下问题：埃博拉开始感染的黏膜处所需的免疫反应；人群在成本和依从性方面的需求；以及每个平台的效力，因为它们含有自然感染呼吸道的病毒。了解鼻内免疫的特性及其应用将产生有效的疫苗，能够在发展中国家和工业化国家有效终结埃博拉及其他新发传染病。
